Insulin Glargine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Insulin Glargine: From Diabetes Mellitus to Pancreatic Agenesis
One-Sentence Summary
Insulin glargine is a long-acting basal insulin analog used for diabetes mellitus. Among 10 TxGNN-predicted new indications, the top-ranked candidates by raw score (e.g., autoimmune oophoritis, stiff person syndrome) carry no supporting clinical trials or literature and are flagged in the evidence pack’s own rationale as likely model noise. The only candidate with actual supporting evidence is Pancreatic Agenesis, backed by 6 publications (no clinical trials), where insulin replacement is mechanistically a near-direct extension of its known use rather than a novel repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes Mellitus (general pharmacological knowledge — not verifiable from this evidence pack; drug not marketed in Taiwan, no license text available) |
| Predicted New Indication | Pancreatic Agenesis |
| TxGNN Prediction Score | 99.43% (rank 118 of predictions) |
| Evidence Level | L4 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for insulin glargine in this evidence pack (Data Gap). Based on known pharmacology, insulin glargine is a long-acting basal insulin analog whose efficacy in diabetes mellitus — replacing deficient or absent endogenous insulin — is well established and forms the standard of care for insulin-deficient states.
Pancreatic agenesis is a rare congenital condition (associated with mutations such as PTF1A or GATA6) in which the pancreas fails to develop normally, resulting in absolute deficiency of insulin-producing beta cells and consequent neonatal or permanent diabetes mellitus. Mechanistically, this is not a distant repurposing target: exogenous insulin is the direct, physiologically necessary replacement therapy for the insulin deficiency caused by the malformed pancreas, analogous to its established role in Type 1 diabetes. The TxGNN model’s high score for this indication likely reflects this direct causal relationship rather than a novel biological hypothesis — it is best understood as an established clinical practice extension rather than a true “new use.”
By contrast, several higher-scoring predictions in this evidence pack (autoimmune oophoritis, thiamine-responsive dysfunction syndrome, stiff person/stiff limb syndrome, opsismodysplasia, and the lipodystrophy cluster) either lack any plausible mechanistic link to insulin, or — in the case of the lipodystrophy predictions — appear to represent the model mistaking a known adverse effect of insulin injection (localized lipohypertrophy/lipoatrophy) for a treatment relationship. None of these are pursued further in this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11727406 | 2001 | Review | Endocrinology and Metabolism Clinics of North America | Reviews insulin therapy in type 2 diabetes, including intensive glucose control benefits shown in UKPDS |
| 12150359 | 2002 | Review | Journal of the American Pharmaceutical Association | Reviews practical aspects of initiating insulin therapy in type 2 diabetes |
| 19322513 | 2009 | Review | Acta Diabetologica | Reviews secondary diabetes from endocrinopathies causing insulin resistance and impaired glucose tolerance |
| 25818213 | 2015 | Cohort (Veterinary) | Journal of Veterinary Internal Medicine | Evaluates pancreatic enzyme markers in diabetic cats without clinically apparent pancreatitis |
| 32871938 | 2020 | Case Report | Medicine | MODY type 5 (pancreatic dysfunction) case treated with GLP-1 receptor agonist, not insulin glargine |
| 18518815 | 2008 | Case Report (Veterinary) | Journal of the American Veterinary Medical Association | Chronic pancreatitis with secondary diabetes in a sea lion treated with insulin |
Note: None of these publications directly study insulin glargine in human pancreatic agenesis; they support the mechanistic rationale (insulin deficiency → insulin therapy) rather than disease-specific efficacy.
US Market Information
Insulin glargine is currently not marketed in Taiwan and no license records are available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Pancreatic agenesis causes an absolute insulin deficiency for which exogenous insulin is a physiologically direct and clinically established replacement, giving this prediction strong mechanistic plausibility. However, no clinical trials or disease-specific studies test insulin glargine in pancreatic agenesis patients — the supporting literature addresses general insulin therapy and related conditions only, placing this at evidence level L4 (mechanism/preclinical reasoning).
To proceed, the following is needed:
- TFDA labeling data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action detail from DrugBank — currently a High-severity data gap (DG002)
- Disease-specific dosing and safety data for neonatal/pediatric permanent diabetes populations, since pancreatic agenesis typically presents in infancy
- Regulatory pathway assessment given insulin glargine is not currently marketed in Taiwan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.